Nikhita Gadi
Nephrology · Hackensack, NJNPI 1982192654
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,910 of the $3,909 with a category attached, or 74.4%. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 77.6% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $3,460 and has fallen 97.5% since, to $86 in 2025.
Across 27 payments — averaging $144.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Calliditas Therapeutics US Inc.$238
- Novartis$216
- Amgen$136
- Novo Nordisk$125
- Aurinia Pharma U.S., Inc.$73
- plus $85 from 3 others
What the payments were for
- Consulting fees$2,91074%
- Food & beverage$99926%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $3,035 |
| Calliditas Therapeutics US Inc. | 4 | $238 |
| Novartis | 12 | $216 |
| Amgen | 1 | $136 |
| Novo Nordisk | 1 | $125 |
| Aurinia Pharma U.S., Inc. | 3 | $73 |
| Veloxis Pharmaceuticals, Inc. | 1 | $34 |
| AstraZeneca | 2 | $33 |
| Nxstage Medical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,909 in reported general payments places this provider in the 80th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 20 | $199 |
| Amlodipine Besylate | 20 | $183 |
| Hydralazine Hcl | 14 | $94 |
| Losartan Potassium | 22 | $86 |
| Furosemide | 14 | $68 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Hackensack
- David SerurHackensack$11K
- Rosy JosephHackensack$5K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.